A new frontier in cancer care is emerging—one that merges diagnosis and therapy into a single, targeted strategy.

In this article from Vizient’s Diagnostic Imaging series, discover how theranostics is transforming oncology by delivering personalized radiopharmaceutical treatments that precisely target cancer cells while minimizing harm to healthy tissue. With growing clinical adoption, strategic investment opportunities, and FDA-approved therapies already in use, theranostics is poised to become the fifth pillar of cancer treatment.